HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Mohsin Hakim John Wallwork Terence English Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hakim, M. Articles by English, T. Search for Related Content PubMed PubMed Citation Articles by Hakim, M. Articles by English, T.

Ann Thorac Surg 1988;46:495-501
© 1988 The Society of Thoracic Surgeons

---

Articles

Cyclosporin A in Cardiac Transplantation: Medium-term Results in 62 Patients

Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, England

Accepted for publication June 8, 1988.

^* Address reprint requests to Dr. Hakim, Division of Thoracic and Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55901

Between March, 1982, and October, 1984, 62 patients underwent orthotopic cardiac transplantation in our institution. Immunosuppression was based on cyclosporin A (Cy A) and low-dose steroids with an initial 10-day course of antithymocyte globulin. Follow-up ranged between 39 and 71 months (mean, 51.7 months). Actuarial survival at 1 year through 5 years was 80.6%, 77.4%, 74.2%, 71.4%, and 63.5%, respectively. Graft atheroma led to graft failure in 6 patients, 4 of whom died between 23 and 55 months after transplantation and 2 of whom had a repeat transplantation at 32 and 53 months. Diastolic hypertension (90 mm Hg or higher) developed in 88% of patients at 1 year. Chronic renal impairment was evident in all patients who survived for 2 years. Mean serum creatinine preoperatively and at 1 year through 4 years was 1.49 ± 0.08 mg/100 ml (± the standard error), 2.01 ± 0.09 mg/100 ml, 2.07 ± 0.09 mg/100 ml, 2.26 ± 0.19 mg/100 ml, and 2.32 ± 0.33 mg/100 ml, respectively. End-stage renal failure requiring regular hemodialysis developed in 3 patients, 2 of whom died. We conclude that in addition to graft atheroma, Cy A-related nephrotoxicity is emerging as a major cause of medium-term and long-term morbidity and mortality. The use of lower doses of Cy A in a triple-therapy protocol, that is, Cy A, azathioprine, and low-dose steroids, could help reduce the extent of renal impairment.

This article has been cited by other articles:

				P. Ferraro, M. Carrier, M. White, G. B. Pelletier, and L. C. Pelletier Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection Ann. Thorac. Surg., August 1, 1995; 60(2): 372 - 376. [Abstract] [PDF]

				B. Hausen, S. Demertzis, R. Rohde, J. M. Albes, H.-J. Schafers, and H.-G. Borst Low-dose cyclosporine therapy in triple-drug immunosuppression for heart transplant recipients Ann. Thorac. Surg., October 1, 1994; 58(4): 999 - 1004. [Abstract] [PDF]

				A. Larsen and J. D. Tobias Nicardipine for the Treatment of Hypertension Following Cardiac Transplantation in a 14-Year-Old Boy Clinical Pediatrics, May 1, 1994; 33(5): 309 - 311. [PDF]